Tarsus Pharmaceuticals, Inc. (TARS)
Data as of , from SEC Form 4 filings.
See up to 3 months of TARS. The 7-day demo opens the 1M and 3M ranges and puts TARS on your watchlist.
Start 7-day demoLatest TARS insider trades
About Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
- IRVINE, CA
- 370
- 2020
- XNAS
TARS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 14 | 62,595 | $5.19M |
| Option exercise | 6 | 1,408 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
TARS insider transactions (Form 4)
6962 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David E. I. Pyott - Director | Option exercise | Common Stock | 201 | - footnote F1 | - | |
| David E. I. Pyott - Director | Option exercise | Restricted Stock Units | 201 | $0.00 | - | |
| ||||||
| Wendy L. Yarno - Director | Option exercise | Common Stock | 302 | - footnote F1 | - | |
| Wendy L. Yarno - Director | Option exercise | Restricted Stock Units | 302 | $0.00 | - | |
| ||||||
| William J. Phd Link - Director | Option exercise | Common Stock | 201 | - footnote F1 | - | |
| William J. Phd Link - Director | Open-market sale | Common Stock | 11,675 | $78.33 footnote F3 | $915K | |
| William J. Phd Link - Director | Open-market sale | Common Stock | 759 | $79.00 footnote F4 | $60K | |
| William J. Phd Link - Director | Open-market sale | Common Stock | 66 | $80.01 | $5K | |
| William J. Phd Link - Director | Option exercise | Restricted Stock Units | 201 | $0.00 | - | |
| ||||||
| Bobak R. Azamian - Officer | Open-market sale | Common Stock | 7,100 | $90.27 footnote F2 | $641K | |
| Bobak R. Azamian - Officer | Open-market sale | Common Stock | 2,900 | $91.27 footnote F4 | $265K | |
| ||||||
| Elizabeth Yeu Lin - Officer | Open-market sale | Common Stock | 5,387 | $85.00 | $458K | |
| Elizabeth Yeu Lin - Officer | Open-market sale | Common Stock | 5,386 | $90.00 | $485K | |
| Elizabeth Yeu Lin - Officer | Open-market sale | Common Stock | 1,590 | $85.00 | $135K | |
| Elizabeth Yeu Lin - Officer | Open-market sale | Common Stock | 1,590 | $90.00 | $143K | |
| Seshadri Neervannan - Officer | Open-market sale | Common Stock | 4,564 | $85.00 | $388K | |
| Bobak R. Azamian - Officer | Open-market sale | Common Stock | 10,000 | $80.06 footnote F2 | $801K | |
| ||||||
| Elizabeth Yeu Lin - Officer | Open-market sale | Common Stock | 4,601 | $73.86 | $340K | |
| Elizabeth Yeu Lin - Officer | Open-market sale | Common Stock | 5,387 | $80.00 | $431K | |
| Elizabeth Yeu Lin - Officer | Open-market sale | Common Stock | 1,590 | $80.00 | $127K | |
| Katherine Goodrich - Director | Grant or award | Restricted Stock Units | 2,417 | $0.00 | - | |
| Katherine Goodrich - Director | Grant or award | Stock Option (right to buy) | 3,837 | $0.00 | - | |
 Andrew D. Goldberg - Director | Grant or award | Stock Option (right to buy) | 3,837 | $0.00 | - | |
| Andrew D. Goldberg - Director | Grant or award | Restricted Stock Units | 2,417 | $0.00 | - | |
| Scott W. Morrison - Director | Grant or award | Stock Option (right to buy) | 3,837 | $0.00 | - | |
| Scott W. Morrison - Director | Grant or award | Restricted Stock Units | 2,417 | $0.00 | - | |
| Bhaskar Chaudhuri - Director | Grant or award | Stock Option (right to buy) | 3,837 | $0.00 | - | |
| Bhaskar Chaudhuri - Director | Grant or award | Restricted Stock Units | 2,417 | $0.00 | - | |
| Wendy L. Yarno - Director | Grant or award | Restricted Stock Units | 1,209 | $0.00 | - | |
| Wendy L. Yarno - Director | Grant or award | Stock Option (right to buy) | 3,837 | $0.00 | - | |
| Wendy L. Yarno - Director | Grant or award | Restricted Stock Units | 2,417 | $0.00 | - | |
| David E. I. Pyott - Director | Grant or award | Restricted Stock Units | 806 | $0.00 | - | |
| David E. I. Pyott - Director | Grant or award | Stock Option (right to buy) | 3,837 | $0.00 | - | |
| David E. I. Pyott - Director | Grant or award | Restricted Stock Units | 2,417 | $0.00 | - | |
| William J. Phd Link - Director | Grant or award | Restricted Stock Units | 2,417 | $0.00 | - | |
| William J. Phd Link - Director | Grant or award | Restricted Stock Units | 806 | $0.00 | - | |
| William J. Phd Link - Director | Grant or award | Stock Option (right to buy) | 3,837 | $0.00 | - | |
| Bobak R. Azamian - Officer | Open-market sale | Common Stock | 4,582 | $61.24 footnote F2 | $281K | |
| Bobak R. Azamian - Officer | Open-market sale | Common Stock | 5,418 | $61.81 footnote F4 | $335K | |
| ||||||
| Jeffrey S. Farrow - Officer | Open-market sale | Common Stock | 14,396 | $60.95 | $877K | |
| Jeffrey S. Farrow - Officer | Option exercise | Restricted Stock Units | 27,881 | $0.00 | - | |
| Jeffrey S. Farrow - Officer | Option exercise | Common Stock | 27,881 | - footnote F1 | - | |
| ||||||
| Katherine Goodrich - Director | Open-market sale | Common Stock | 2,954 | $62.08 | $183K | |
| William J. Phd Link - Director | Open-market sale | Common Stock | 10,572 | $61.97 footnote F2 | $655K | |
| William J. Phd Link - Director | Open-market sale | Common Stock | 1,928 | $62.94 footnote F3 | $121K | |
| ||||||
| Scott W. Morrison - Director | Option exercise | Restricted Stock Units | 2,954 | $0.00 | - | |
| Scott W. Morrison - Director | Option exercise | Common Stock | 2,954 | - footnote F1 | - | |
| ||||||
| William J. Phd Link - Director | Option exercise | Common Stock | 2,954 | - footnote F1 | - | |
| William J. Phd Link - Director | Option exercise | Restricted Stock Units | 2,954 | $0.00 | - | |
| ||||||
| Bhaskar Chaudhuri - Director | Option exercise | Restricted Stock Units | 2,954 | $0.00 | - | |
| Bhaskar Chaudhuri - Director | Option exercise | Common Stock | 2,954 | - footnote F1 | - | |
| ||||||
| Katherine Goodrich - Director | Option exercise | Restricted Stock Units | 2,954 | $0.00 | - | |
| Katherine Goodrich - Director | Option exercise | Common Stock | 2,954 | - footnote F1 | - | |
| ||||||
| Wendy L. Yarno - Director | Option exercise | Common Stock | 2,954 | - footnote F1 | - | |
| Wendy L. Yarno - Director | Option exercise | Restricted Stock Units | 2,954 | $0.00 | - | |
| ||||||
| Andrew D. Goldberg - Director | Option exercise | Common Stock | 2,954 | - footnote F1 | - | |
| Andrew D. Goldberg - Director | Option exercise | Restricted Stock Units | 2,954 | $0.00 | - | |
| ||||||
| David E. I. Pyott - Director | Option exercise | Common Stock | 1,383 | - footnote F1 | - | |
| David E. I. Pyott - Director | Option exercise | Restricted Stock Units | 1,383 | $0.00 | - | |
| ||||||
| Seshadri Neervannan - Officer | Open-market sale | Common Stock | 2,989 | $66.75 | $200K | |
 Dianne C. Whitfield - Officer | Open-market sale | Common Stock | 4,029 | $69.42 | $280K | |
| Dianne C. Whitfield - Officer | Open-market sale | Common Stock | 4,071 | $68.71 | $280K | |
| Dianne C. Whitfield - Officer | Open-market sale | Common Stock | 4,174 | $67.00 | $280K | |
 Bryan Wahl - Officer | Open-market sale | Common Stock | 4,084 | $69.42 | $284K | |
| Bryan Wahl - Officer | Open-market sale | Common Stock | 4,125 | $68.71 | $283K | |
| Bryan Wahl - Officer | Open-market sale | Common Stock | 4,231 | $67.00 | $283K | |
| Seshadri Neervannan - Officer | Open-market sale | Common Stock | 3,125 | $69.42 | $217K | |
| Seshadri Neervannan - Officer | Open-market sale | Common Stock | 3,610 | $68.71 | $248K | |
| Seshadri Neervannan - Officer | Open-market sale | Common Stock | 4,589 | $67.00 | $307K | |
Item 9.01
Item 2.01, 8.01, 9.01
Item 2.02, 9.01
Item 1.01, 3.02, 8.01, 9.01
Recent TARS Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| WILLIAM J LINK | DIRECTOR | 12,500 | $980K | View on EDGAR | |
| Neervannan Seshadri | Officer | 4,564 | $388K |
TARS insider trading FAQ
What is the latest insider trade for TARS?
Tarsus Pharmaceuticals, Inc. (TARS) had 8 insider filings in the last 90 days, with the most recent on 2026-09-17. The full record for TARS runs to 62 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TARS stock?
No insider purchases of TARS were filed in the last 90 days.
How many insiders are selling TARS stock?
14 insider sales of TARS were filed in the last 90 days, totaling $5.19M.
Where can I see TARS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TARS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - David E. I. Pyott view on EDGAR
- - Wendy L. Yarno view on EDGAR
- - William J. Phd Link view on EDGAR
- - Bobak R. Azamian view on EDGAR
- - Elizabeth Yeu Lin view on EDGAR
- - Seshadri Neervannan view on EDGAR
- - Bobak R. Azamian view on EDGAR
- - Elizabeth Yeu Lin view on EDGAR
- - Katherine Goodrich view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where TARS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TARS with a 7-day demo
- TARS on your watchlist
- Every TARS Form 4 filing on record
- Up to 3 months of TARS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
